Neurological adverse effect / neurological deficit

• (2024): Li J+, Endocr Metab Immune Disord Drug Targets Oct, Online ahead of print (association) (pharmacovigilance / pharmacoepidemiology)

Neuromyopathy

• (2022): Attardo S+, Int J Mol Sci 23(15), 8364 [REVIEW]

Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)

• (2023): Su FY+, Horm Metab Res Nov, Online ahead of print (with concomitant medication)

Myalgia/Myositis/Myopathy/Myotoxicity

• (2025): Alshammari AS+, Ther Clin Risk Manag 21, 861-867 (association; with ticagrelor) (drug interaction)
• (2025): Sridharan K+, Curr Rev Clin Exp Pharmacol Mar, Online ahead of print [REVIEW] (pharmacogenomics)
• (2023): Wei C+, J Clin Med 12(10), 3548 (with daptomycin; association)
• (2023): Yow HY+, Asian Biomed (Res Rev News) 17(3), 95-114 [REVIEW] (pharmacogenomics)

Myasthenia gravis

• (2023): Drug Ther Bull Dec, Online ahead of print (UK MHRA; September 2023; Statins: very infrequent reports of myasthenia gravis. Globally, there has been a very small number of reports of new-onset or aggravation of pre-existing myasthenia gravis with atorvastatin, pravastatin, lovastatin, fluvastatin, simvastatin, rosuvastatin and pitavastatin (single-ingredient and fixed-dose combination products). Advise patients taking statins to be alert to new symptoms for myasthenia gravis, or worsening symptoms of pre-existing myasthenia gravis, and to seek medical advice if these occur.)

Necrotizing myopathy / immune-mediated necrotizing myopathy

• (2022): Somagutta MKR+, Reumatologia 60(1), 63-69 [REVIEW]
• (2017): Tiniakou E+, Curr Opin Rheumatol 29(6), 604-611 [REVIEW]

Rhabdomyolysis

• (2022): Kunakorntham P+, BMC Med Inform Decis Mak 22(1), 233

Ocular adverse effect

• (2015): Bahrami B+, Med J Aust 203(9), 365 [REVIEW]
• (2015): Mizranita V+, Int J Clin Pharm 37(5), 844-50 [REVIEW]